Clinical trials for medicines: notifiable trials

AI Summary

Effective April 28, 2026, this guidance outlines the streamlined regulatory framework for 'notifiable' clinical trials under the UK Medicines for Human Use (Clinical Trials) Regulations 2004, as updated by the 2025 Amendment Regulations. The guidance applies to all pharmaceutical companies and research organizations (sponsors) conducting clinical trials in the UK. Unlike specific inspection reports, this document establishes a proactive authorization process rather than detailing past violations. Under this new framework, sponsors can receive automatic licensing authority authorization for low-risk trials within 14 days of validation. However, trials cannot commence until a final combined approval, including an Ethics Committee review, is issued within 30 days. To comply, sponsors must meticulously assess their trials against specific inclusion and exclusion criteria and document their reasoning. Required actions include submitting a 'Confirmation of notifiable trial criteria' form alongside the standard application and explicitly identifying the trial as notifiable in the cover letter. Incorrectly categorizing a trial as notifiable may result in application invalidation and required resubmission. The licensing authority maintains oversight through audits and retains the right to conduct full reviews if a trial presents increased risks or concerns regarding the study design or investigational products. Sponsors are responsible for ensuring all trial activities delegated to third parties also adhere to these updated requirements to maintain regulatory compliance.